• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Kodiak Sciences Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

    3/29/23 12:50:58 PM ET
    $AGBA
    $AMBI
    $ANGN
    $ARCT
    Investment Managers
    Finance
    Environmental Services
    Industrials
    Get the next $AGBA alert in real time by email

    Gainers

    • LogicMark, Inc. (NASDAQ:LGMK) shares jumped 76.1% to $0.2466 after the company announced financial results for the year ended 2022. The company reported FY22 revenue of $11.9 million.
    • Ambipar Emergency Response (NASDAQ:AMBI) surged 40.9% to $10.95.
    • Local Bounti Corporation (NYSE:LOCL) gained 35% to $0.6102 after the company announced it secured up to $145 million of additional financing to support growth. The company also reported Q4 financial results and issued guidance.
    • WaveDancer, Inc. (NASDAQ:WAVD) jumped 30% to $0.3450.
    • CBL International Limited (NASDAQ:BANL) surged 26.8% to $8.64.
    • Kodiak Sciences Inc. (NASDAQ:KOD) gained 18.3% to $5.80 after posting a narrower-than-expected quarterly loss.
    • Helbiz, Inc. (NASDAQ:HLBZ) gained 16.8% to $0.1343. Helbiz posted FY22 revenue of $15.5 million, up 21% year over year.
    • Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) shares climbed 16.5% to $18.05 after the company reported better-than-expected Q4 EPS and sales results.
    • Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) gained 16.3% to $2.14.
    • Bird Global, Inc. (NASDAQ:BRDS) rose 16.2% to $0.2252 after jumping 42% on Tuesday.
    • Erasca, Inc. (NASDAQ:ERAS) gained 15.3% to $3.16. Erasca Chairman & CEO Jonathan Lim acquired a total of 100,000 shares at an average price of $2.84.
    • Lululemon Athletica Inc. (NASDAQ:LULU) shares climbed 15.1% to $368.73 after the company reported better-than-expected Q4 results and issued strong guidance.
    • Atai Life Sciences N.V. (NASDAQ:ATAI) rose 14.6% to $1.5250.
    • Cipher Mining Inc. (NASDAQ:CIFR) gained 13.7% to $2.1604.
    • Tempest Therapeutics, Inc. (NASDAQ:TPST) climbed 13.1% to $1.98. Tempest Therapeutics recently posted a Q4 loss of $0.63 per share.
    • Enovix Corporation (NASDAQ:ENVX) gained 13% to $12.70. The company announced a new manufacturing partner and selected the location for its next high-volume manufacturing facility.
    • N-able, Inc. (NYSE:NABL) shares rose 12.6% to $13.72. N-able will replace iStar Incin the S&P SmallCap 600 on Monday, April 3.
    • Angion Biomedica Corp. (NASDAQ:ANGN) gained 12.5% to $0.54.
    • AST SpaceMobile, Inc. (NASDAQ:ASTS) jumped 11% to $6.24.
    • Riot Platforms, Inc (NASDAQ:RIOT) shares rose 10% to $8.92 amid a rise in Bitcoin.
    • Marathon Digital Holdings, Inc. (NASDAQ:MARA) shares surged 10% to $7.92 amid a rise in Bitcoin.
    • Stratasys Ltd. (NASDAQ:SSYS) jumped 9.8% to $15.50 after Nano Dimension increased its offer to acquire the company to $19.55 per share in cash.
    • Hut 8 Mining Corp (NASDAQ:HUT) gained 9.4% to $1.7607 amid strength in cryptocurrencies.
    • Cal-Maine Foods, Inc. (NASDAQ:CALM) shares climbed 8.3% to $58.87 after the company reported better-than-expected financial results for its fiscal third quarter.
    • Rivian Automotive, Inc. (NASDAQ:RIVN) climbed 7.9% to $13.98. Needham reiterated Rivian Automotive with a Buy and maintained a $26 price target.
    • Micron Technology, Inc. (NASDAQ:MU) gained 6.2% to $62.99 following fiscal second-quarter financial results.

    Losers

    • ProQR Therapeutics N.V. (NASDAQ:PRQR) fell 32.7% to $2.41. ProQR Therapeutics posted a FY loss of €0.91 per share.
    • bluebird bio, Inc. (NASDAQ:BLUE) dropped 30.6% to $2.9953 after the company reported Q4 and full year 2022 financial results. Also, a Bloomberg report suggesting Bluebird Bio expects a delay on its FDA sickle cell drug application is also impacting the stock.
    • Sharecare, Inc. (NASDAQ:SHCR) shares dipped 27.3% to $1.5486 after the company reported Q4 results.
    • Minim, Inc. (NASDAQ:MINM) fell 24.1% to $0.1088 after reporting Q4 results.
    • Shift Technologies, Inc (NASDAQ:SFT) shares dropped 23.8% to $1.29 after reporting downbeat quarterly sales. Shift also announced regaining compliance with Nasdaq listing requirement.
    • Near Intelligence, Inc. (NASDAQ:NIR) fell 20.8% to $2.85 after the company reported Q4 financial results.
    • Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) dipped 18.2% to $1.21 after the company reported a 17.6% year-over-year decline in revenue in FY22 to $25.9 million.
    • Stem, Inc. (NYSE:STEM) dropped 16.8% to $5.18 after the company announced a proposed $175 million green convertible senior notes offering.
    • AGBA Group Holding Limited (NASDAQ:AGBA) dropped 16.1% to $2.1801.
    • GlycoMimetics, Inc. (NASDAQ:GLYC) fell 15.3% to $1.1850 after posting a wider-than-expected quarterly loss.
    • Codiak BioSciences, Inc. (NASDAQ:CDAK) dipped 13.3% to $0.1646.
    • Draganfly Inc. (NASDAQ:DPRO) fell 13.3% to $1.24. Draganfly announced pricing of $8 million underwritten public offering of 8 million shares of common stock at a price of $1 per share to secure growth capital.
    • Gulf Island Fabrication, Inc. (NASDAQ:GIFI) dropped 13.2% to $3.67 following Q4 results.
    • El Pollo Loco Holdings, Inc. (NASDAQ:LOCO) fell 12.9% to $8.97.
    • SomaLogic, Inc. (NASDAQ:SLGC) fell 9.5% to $1.29 after the company posted a wider-than-expected Q4 loss.
    • UniFirst Corporation (NYSE:UNF) dropped 9.3% to $175.14 after posting Q2 results.
    • IceCure Medical Ltd (NASDAQ:ICCM) fell 7.8% to $1.1799 after gaining 14% on Tuesday. IceCure Medical secured regulatory approval in China for commercial use of its IceSense3 Disposable Cryoprobes.

    Now Read This: Bitcoin Surges Past This Key Level; Mask Network, Frax Share Among Top Gainers

    Get the next $AGBA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGBA
    $AMBI
    $ANGN
    $ARCT

    CompanyDatePrice TargetRatingAnalyst
    Micron Technology Inc.
    $MU
    4/3/2026Buy → Hold
    Erste Group
    Micron Technology Inc.
    $MU
    4/2/2026Buy → Hold
    Erste Group
    Rivian Automotive Inc.
    $RIVN
    4/1/2026$14.00Underperform → Neutral
    DA Davidson
    AtaiBeckley Inc.
    $ATAI
    3/27/2026$12.00Buy
    Deutsche Bank
    Draganfly Inc.
    $DPRO
    3/25/2026$14.00 → $12.00Buy
    Needham
    Hut 8 Corp.
    $HUT
    3/23/2026$136.00Buy
    Arete
    N-able Inc.
    $NABL
    3/23/2026Outperform → Underperform
    William Blair
    Micron Technology Inc.
    $MU
    3/19/2026Buy → Hold
    Summit Insights
    More analyst ratings

    $AGBA
    $AMBI
    $ANGN
    $ARCT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

    For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

    12/8/23 11:12:21 AM ET
    $BLUE
    $VRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 17, 2022 - FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions

    For Immediate Release: August 17, 2022 Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.  “Today’s approval is an important advance in the treatment of beta-thalassemia, particularly in individuals who require ongoing

    8/17/22 2:12:27 PM ET
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGBA
    $AMBI
    $ANGN
    $ARCT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    N-able to Host First Quarter Earnings Conference Call on May 7, 2026

    N-able, Inc. (NYSE:NABL), a global cybersecurity company delivering business resilience, today announced that it will host a conference call to discuss its financial results for the first quarter of 2026 at 8:30 a.m. ET on May 7, 2026. A live webcast of the call will be available on the N-able Investor Relations website at http://investors.n-able.com. A replay of the webcast will be available on a temporary basis shortly after the event. N-able will issue its earnings release highlighting its first quarter results prior to the start of the conference call on May 7, 2026. About N-able N-able protects businesses from evolving cyberthreats. Our AI-powered cybersecurity platform delivers

    4/23/26 4:30:00 PM ET
    $NABL
    Computer Software: Prepackaged Software
    Technology

    Chicken Tenders, but Make Them Loco

    COSTA MESA, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- El Pollo Loco, Inc., the nation's leading fire-grilled chicken restaurant chain, is turning up the heat and officially entering the tenders chat. On April 23, El Pollo Loco will introduce its Loco Tenders ™, the brand's take on America's favorite finger food. Available for a limited time only, Loco Tenders come in 2-, 3-, or 4-piece meals and in two delicious varieties: Spicy: Crispy chicken tenders made with 100% all white meat chicken, fried to perfection and seasoned in a blend of bold Mexican spices.Classic: Crispy chicken tenders made with 100% all white meat chicken, fried to perfection. But what's a Tender without a dipping s

    4/23/26 9:01:00 AM ET
    $LOCO
    Restaurants
    Consumer Discretionary

    Stratasys Conference Call to Discuss First Quarter 2026 Financial Results

    Stratasys Ltd. (NASDAQ:SSYS) will release financial results for the first quarter ended March 31, 2026, on Thursday, May 7, 2026. The Company plans to hold the conference call to discuss its first quarter 2026 financial results on Thursday, May 7, 2026, at 8:30 a.m. (ET). The investor conference call will be available via live webcast on the Stratasys Web site at investors.stratasys.com, or directly at the following web address: https://event.choruscall.com/mediaframe/webcast.html?webcastid=jBx4uZ5o To participate by telephone, the U.S. toll-free number is 877-407-0619 and the international dial-in is +1-412-902-1012. Investors are advised to dial into the call at least ten minutes pr

    4/23/26 7:00:00 AM ET
    $SSYS
    Computer peripheral equipment
    Technology

    $AGBA
    $AMBI
    $ANGN
    $ARCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Flatley Jay T bought $25,281 worth of shares (1,830 units at $13.81) and sold $11,775 worth of shares (580 units at $20.30), increasing direct ownership by 0.78% to 162,070 units (SEC Form 4)

    4 - Rivian Automotive, Inc. / DE (0001874178) (Issuer)

    3/5/26 5:10:12 PM ET
    $RIVN
    Auto Manufacturing
    Industrials

    Director Liu Teyin M bought $7,821,723 worth of shares (23,200 units at $337.14), increasing direct ownership by 856% to 25,910 units (SEC Form 4)

    4 - MICRON TECHNOLOGY INC (0000723125) (Issuer)

    1/15/26 7:07:13 PM ET
    $MU
    Semiconductors
    Technology

    Director Larson Keith R bought $50,000 worth of shares (625 units at $80.00) (SEC Form 4)

    4 - AST SpaceMobile, Inc. (0001780312) (Issuer)

    12/29/25 6:00:02 PM ET
    $ASTS
    Telecommunications Equipment
    Consumer Discretionary

    $AGBA
    $AMBI
    $ANGN
    $ARCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Micron downgraded by Erste Group

    Erste Group downgraded Micron from Buy to Hold

    4/3/26 10:44:59 AM ET
    $MU
    Semiconductors
    Technology

    Micron downgraded by Erste Group

    Erste Group downgraded Micron from Buy to Hold

    4/2/26 9:25:13 AM ET
    $MU
    Semiconductors
    Technology

    Rivian Automotive upgraded by DA Davidson with a new price target

    DA Davidson upgraded Rivian Automotive from Underperform to Neutral and set a new price target of $14.00

    4/1/26 9:04:14 AM ET
    $RIVN
    Auto Manufacturing
    Industrials

    $AGBA
    $AMBI
    $ANGN
    $ARCT
    SEC Filings

    View All

    SEC Form DEFA14A filed by Local Bounti Corporation

    DEFA14A - Local Bounti Corporation/DE (0001840780) (Filer)

    4/23/26 4:16:45 PM ET
    $LOCL
    Farming/Seeds/Milling
    Consumer Staples

    SEC Form DEF 14A filed by Local Bounti Corporation

    DEF 14A - Local Bounti Corporation/DE (0001840780) (Filer)

    4/23/26 4:16:06 PM ET
    $LOCL
    Farming/Seeds/Milling
    Consumer Staples

    SEC Form 6-K filed by IceCure Medical Ltd.

    6-K - IceCure Medical Ltd. (0001584371) (Filer)

    4/22/26 5:28:16 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    $AGBA
    $AMBI
    $ANGN
    $ARCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Craig Kevin James

    4 - AtaiBeckley Inc. (0002081043) (Issuer)

    4/22/26 5:32:52 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Gomez Aidan N.

    4 - Rivian Automotive, Inc. / DE (0001874178) (Issuer)

    4/22/26 4:43:02 PM ET
    $RIVN
    Auto Manufacturing
    Industrials

    SEC Form 4 filed by Schwartz Sanford Harold

    4 - Rivian Automotive, Inc. / DE (0001874178) (Issuer)

    4/22/26 4:42:15 PM ET
    $RIVN
    Auto Manufacturing
    Industrials

    $AGBA
    $AMBI
    $ANGN
    $ARCT
    Leadership Updates

    Live Leadership Updates

    View All

    lululemon Names Proven Brand Builder Heidi O'Neill as Chief Executive Officer

    O'Neill is a visionary, consumer-focused executive with more than three decades of experience leading brand strategy, product innovation, and operational execution on a global scale lululemon athletica inc. (NASDAQ:LULU) today announced that, following a comprehensive search process, the company's Board of Directors has unanimously approved the appointment of industry veteran Heidi O'Neill as the company's next Chief Executive Officer. Ms. O'Neill will start as CEO and join the Board effective September 8, 2026, and will be based in Vancouver. "Heidi is an inspiring leader and proven, consumer-driven brand strategist, with a rare ability to both imagine a new future for a brand and to c

    4/22/26 4:05:00 PM ET
    $LULU
    Apparel
    Consumer Discretionary

    Inspira Technologies Appoints Yoav Rozanovich as Chief Business Officer to Drive Immediate Revenue Growth and Quantum Expansion

    RA'ANANA, Israel, April 14, 2026 (GLOBE NEWSWIRE) -- Inspira Technologies OXY B.H.N. Ltd (NASDAQ:IINN, IINNW)) ("Inspira Technologies" or the "Company") today announced the appointment of Mr. Yoav Rozanovich as Chief Business Officer ("CBO") of Inspira Technologies, reinforcing its commercial execution capabilities following its expansion into quantum computing connectivity and the acquisition of the Additive Manufacturing of Electronics ("AME") business from Nano Dimension Ltd. (NASDAQ:NNDM) ("Nano Dimension"). Proven Commercial LeadershipMr. Rozanovich brings international experience across additive manufacturing, advanced electronics, and complex systems integration. From November 2021

    4/14/26 8:01:00 AM ET
    $IINN
    $NNDM
    $SSYS
    Medical/Dental Instruments
    Health Care
    Electrical Products
    Technology

    Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

    Adds dedicated business development leadership to support Tempest's strategic prioritiesWill lead China outreach and cross-border partnership effortsTo support ongoing partnering discussions for Phase 3-ready amezalpat program, including potential China development opportunities BRISBANE, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced the appointment of Andrew Fang, Ph.D., as Head of Business Development. Dr. Fang will lead Tempest's global business development efforts, including strategic partners

    4/14/26 8:00:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGBA
    $AMBI
    $ANGN
    $ARCT
    Financials

    Live finance-specific insights

    View All

    N-able to Host First Quarter Earnings Conference Call on May 7, 2026

    N-able, Inc. (NYSE:NABL), a global cybersecurity company delivering business resilience, today announced that it will host a conference call to discuss its financial results for the first quarter of 2026 at 8:30 a.m. ET on May 7, 2026. A live webcast of the call will be available on the N-able Investor Relations website at http://investors.n-able.com. A replay of the webcast will be available on a temporary basis shortly after the event. N-able will issue its earnings release highlighting its first quarter results prior to the start of the conference call on May 7, 2026. About N-able N-able protects businesses from evolving cyberthreats. Our AI-powered cybersecurity platform delivers

    4/23/26 4:30:00 PM ET
    $NABL
    Computer Software: Prepackaged Software
    Technology

    Stratasys Conference Call to Discuss First Quarter 2026 Financial Results

    Stratasys Ltd. (NASDAQ:SSYS) will release financial results for the first quarter ended March 31, 2026, on Thursday, May 7, 2026. The Company plans to hold the conference call to discuss its first quarter 2026 financial results on Thursday, May 7, 2026, at 8:30 a.m. (ET). The investor conference call will be available via live webcast on the Stratasys Web site at investors.stratasys.com, or directly at the following web address: https://event.choruscall.com/mediaframe/webcast.html?webcastid=jBx4uZ5o To participate by telephone, the U.S. toll-free number is 877-407-0619 and the international dial-in is +1-412-902-1012. Investors are advised to dial into the call at least ten minutes pr

    4/23/26 7:00:00 AM ET
    $SSYS
    Computer peripheral equipment
    Technology

    Cipher Digital Announces Date of First Quarter 2026 Business Update Conference Call

    NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Cipher Digital Inc. (NASDAQ:CIFR) ("Cipher" or the "Company") today announced it will provide a business update and release its first quarter 2026 financial results before U.S. markets open on Tuesday, May 5th, 2026. Cipher will host a conference call and webcast that day at 8:00 a.m. Eastern Time. The live webcast and a webcast replay of the conference call can be accessed from the investor relations section of Cipher's website at https://investors.cipherdigital.com. About CipherCipher develops and operates industrial-scale data centers engineered for next-generation computing at the highest standards of innovation, precision, and excellence.

    4/21/26 4:05:00 PM ET
    $CIFR
    Finance: Consumer Services
    Finance

    $AGBA
    $AMBI
    $ANGN
    $ARCT
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at GlycoMimetics Inc. on Jun 20 Indicate?

    Recently, on June 20, 2024, an insider purchase was made at GlycoMimetics Inc., grabbing the attention of investors. According to the SEC Form 4 filing, SVP Finance, CFO Hahn Brian M. bought $4,335 worth of shares (17,500 units at $0.25), boosting direct ownership by 33% to 70,643 units. Insider transactions are closely monitored by investors as they can provide insights into the company's prospects and the confidence of insiders in the business. Let's delve deeper into the recent insider purchase and analyze any potential patterns or significance in comparison to other insider transactions at GlycoMimetics Inc. In early April 2024, Goldberg Mark Alan was granted 4,584 shares, augmenting di

    6/20/24 6:20:00 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGBA
    $AMBI
    $ANGN
    $ARCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Pieris Pharmaceuticals Inc.

    SC 13G/A - PALVELLA THERAPEUTICS, INC. (0001583648) (Subject)

    12/17/24 5:42:35 PM ET
    $PIRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by LogicMark Inc.

    SC 13D/A - LogicMark, Inc. (0001566826) (Subject)

    12/3/24 3:35:39 PM ET
    $LGMK
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by GlycoMimetics Inc.

    SC 13G - GLYCOMIMETICS INC (0001253689) (Subject)

    11/27/24 2:22:44 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care